Peptidomimetic compounds or derivatives thereof and their use
By designing peptide-like compounds with specific structures to inhibit 3CL protease, the problems of drug resistance and mutation risk of existing antiviral drugs have been solved, and effective inhibition and treatment of viruses such as SARS-CoV-2 have been achieved.
CN122404474APending Publication Date: 2026-07-17ZHUHAI NOBEL INST OF BIOMEDICINE CO LTD +2
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHUHAI NOBEL INST OF BIOMEDICINE CO LTD
- Filing Date
- 2025-01-16
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing SARS-CoV-2 3CL protease inhibitors have drug resistance issues, and the novel coronavirus has a high risk of mutation, lacking novel, highly effective, and low-toxicity broad-spectrum antiviral drugs.
Method used
This invention provides a peptide-like compound or its derivative that, through the design of a compound with a specific structure, inhibits the activity of 3CL protease, thereby achieving effective inhibition of viruses such as SARS-CoV-2.
Benefits of technology
The compounds and their derivatives can effectively inhibit 3CL protease and are used to treat and prevent viral infections such as SARS-CoV-2, exhibiting good biological activity and low toxicity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122404474A_ABST
Abstract
拟肽类化合物或其衍生物及它们的应用。本申请提供了一种拟肽类化合物及其衍生物，具有式(I)所示的化合物、或其异构体、药学上可接受的盐或前药。本申请的化合物及其衍生物可以有效抑制3CL蛋白酶，可制备为治疗和 / 或预防SARS‑CoV，SARS‑CoV‑2，MERS，HBV或HCV病毒感染类疾病的药物，其化学结构新颖，并具有良好的生物学活性。
Need to check novelty before this filing date? Find Prior Art